FDA issues EUA for COVID-19 prevention drug

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for pemivibart for the prevention of COVID-19 in certain immunocompromised adults and adolescents. The drug is distributed under the brand name Pemgarda and is for individuals who are not currently infected with COVID-19, have immune compromise, and are unlikely to have adequate immune response to COVID-19 vaccination.